辅酶Q10补充剂调节肝脏脂质学变化,减轻小鼠代谢功能障碍相关的脂肪肝炎
Yula Go1, Heeju Joung2, Sang Yun Han2
1Department of Food & Nutrition, Kyung Hee University, Seoul 02447, Republic of Korea.
Nutrients
|February 27, 2026
概括
辅酶Q10 (CoQ) 补充剂减少了与代谢功能障碍相关的脂肪肝炎 (MASH) 的小鼠模型中的肝损伤. CoQ改变了肝脏的脂平衡,这表明它在MASH营养治疗中发挥了作用.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 营养科学 营养科学
- 利皮多米克 (Lipidomics) 是一种消化剂.
背景情况:
- 代谢功能障碍相关的脂肪肝炎 (MASH) 是一种不断增长的肝脏疾病,治疗方法很少.
- 改变的膜脂质与MASH病理生理学有关.
- 对于MASH脂质变化的营养干预措施尚未明确定义.
研究的目的:
- 在MASH的小鼠模型中研究辅酶Q10 (CoQ) 对肝脂变化的影响.
- 评估CoQ对由甲素和胆缺乏 (MCD) 饮食诱导的肝脂质体重塑的影响.
主要方法:
- 给小鼠食的是控制饮食或MCD饮食,一些MCD食的小鼠接受了CoQ补充剂.
- 使用基于LC-MS的脂管学分析了肝脂质配置文件.
- 与脂质代谢相关的基因表达通过实时PCR量化.
主要成果:
- 补充CoQ减少了MCD饮食引起的肝损伤和肝酶 (ALT,AST) 的降低.
- MASH的发展改变了肝脏的脂和脂样本.
- CoQ增加了氨酸胆 (PC) 和减少了氨酸乙醇胺 (PE) 种类,提高了PC与PE的比率,并上调了Pemt.
结论:
- 在被食MCD饮食的小鼠中,CoQ补充剂减弱了MASH.
- CoQ调节了肝脏脂平衡,这表明它有可能作为MASH相关脂质失调的营养干预措施.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
244
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
244
Lipid Catabolism
1.2K
Triglycerides serve as crucial long-term energy storage molecules in microorganisms, providing a dense source of metabolic energy. Their breakdown is mediated by lipases, which hydrolyze triglycerides into glycerol and free fatty acids. Each of these components follows distinct metabolic pathways, ultimately contributing to ATP synthesis and cellular energy homeostasis.Glycerol MetabolismGlycerol, released from triglyceride hydrolysis, is phosphorylated by glycerol kinase to form...
1.2K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
316
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
316
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
302
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
302


